Revenue by Product

6 Months Ended

Jun. 30, 2019

Segment Reporting [Abstract]

Revenue by Product

Revenue by Product 

The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the CEO. The CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. 

The following table presents a summary of total revenues by these products: 

	Three Months Ended June 30,					Six Months Ended June 30,
Revenues by Product:	2019			2018		2019		2018
Bloxiverz	$	2,358		$	5,544	$	4,926	$	13,035
Vazculep	9,410			11,377		18,883		24,338
Akovaz	5,946			11,875		9,738		22,092
Other	(160		)	320		444		2,812
Total product sales	17,554			29,116		33,991		62,277
License revenue	—			114		—		246
Total revenues	$	17,554		$	29,230	$	33,991	$	62,523